Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20654103 | 0.80 | HRH3 (0.41) | HRH3ALDH1A1GAAUSP2THRB | |
| SCHEMBL21933937 | 0.77 | — | — | |
| SCHEMBL20654101 | 0.74 | CYP2A13 (0.35) | ALDH1A1SLC6A3 | |
| SCHEMBL20654040 | 0.74 | CYP2A13 (0.35) | ALDH1A1SLC6A3 | |
| SCHEMBL18727392 | 0.74 | HRH3 (0.44) | HRH3ALDH1A1GAAUSP2THRB | |
| SCHEMBL3378090 | 0.73 | HRH3 (0.37) | HRH3ALDH1A1GAATHRBKDM4E | |
| SCHEMBL3378092 | 0.73 | HRH3 (0.37) | HRH3ALDH1A1GAATHRBKDM4E | |
| SCHEMBL12014128 | 0.72 | HRH3 (0.35) | HRH3ALDH1A1GAAUSP2THRB | |
| SCHEMBL20755339 | 0.72 | CHRM5 (0.42) | HRH3ALDH1A1THRBMAPT | |
| SCHEMBL21450672 | 0.71 | THRB (0.39) | HRH3ALDH1A1GAAUSP2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291018-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291018-A1 | TAM KINASE INHIBITORS | MAP3K1, PIK3CA, MAP3K5 | HRH3 2027/4885ALDH1A1 3392/4885GAA 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.